Κλινική Τεκμηρίωση
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomized, double-blind, placebo-controlled proof-of-concept clinical trial
Marios C Pantzaris et al
Objective: To assess whether three novel interventions, formulated based on a systems medicine therapeutic concept, reduced disease activity in patients with relapsing–remitting multiple sclerosis (MS) who were either treated or not with disease modifying treatment.
Design: A 30-month randomized, double-blind, placebo-controlled, parallel design, phase II proof-of-concept clinical study.
Settings: Cyprus Institute of Neurology and Genetics.